Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Peter Thomas Lansbury, Ph.D.


Cell System Characterization of a Dopamine-æ-Synuclein Adduct Implicated in Parkinson's Disease
Summer, 06/17/02 - 08/23/02

The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
  1. R21NS053749 (LANSBURY, PETER T) Sep 30, 2005 - Aug 31, 2006
    A High-Throughput Assay-SOD1 Aggregation Inhibitors(RMI)
    Role: Principal Investigator
  2. R03NS051243 (LANSBURY, PETER T) Apr 1, 2005 - Mar 31, 2007
    Discovery of highly toxic synuclein sequence variants
    Role: Principal Investigator
  3. R21NS047420 (LANSBURY, PETER T) Jul 1, 2004 - Jun 30, 2006
    High Throughout Assay to Probe UCH-L1 Ligase Inhibitors
    Role: Principal Investigator
  4. P50NS038375 (LANSBURY, PETER T) Aug 1, 2000 - Sep 5, 2005
    Familial Parkinson's Disease: Clues to Pathogenesis
    Role: Principal Investigator
  5. P01AG014366 (LANSBURY, PETER T) Jul 15, 1998 - May 31, 2003
    Role: Principal Investigator

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. den Heijer JM, Cullen VC, Quadri M, Schmitz A, Hilt DC, Lansbury P, Berendse HW, van de Berg WDJ, de Bie RMA, Boertien JM, Boon AJW, Contarino MF, van Hilten JJ, Hoff JI, van Mierlo T, Munts AG, van der Plas AA, Ponsen MM, Baas F, Majoor-Krakauer D, Bonifati V, van Laar T, Groeneveld GJ. A Large-Scale Full GBA1 Gene Screening in Parkinson's Disease in the Netherlands. Mov Disord. 2020 Jul 02. PMID: 32618053.
  2. Di Martino S, Tardia P, Cilibrasi V, Caputo S, Mazzonna M, Russo D, Penna I, Realini N, Margaroli N, Migliore M, Pizzirani D, Ottonello G, Bertozzi SM, Armirotti A, Nguyen D, Sun Y, Bongarzone ER, Lansbury P, Liu M, Skerlj R, Scarpelli R. Lead Optimization of Benzoxazolone Carboxamides as Orally Bioavailable and CNS Penetrant Acid Ceramidase Inhibitors. J Med Chem. 2020 Apr 09; 63(7):3634-3664. PMID: 32176488.
  3. Cuddy LK, Wani WY, Morella ML, Pitcairn C, Tsutsumi K, Fredriksen K, Justman CJ, Grammatopoulos TN, Belur NR, Zunke F, Subramanian A, Affaneh A, Lansbury PT, Mazzulli JR. Stress-Induced Cellular Clearance Is Mediated by the SNARE Protein ykt6 and Disrupted by a-Synuclein. Neuron. 2019 12 04; 104(5):869-884.e11. PMID: 31648898.
  4. Zheng J, Chen L, Skinner OS, Ysselstein D, Remis J, Lansbury P, Skerlj R, Mrosek M, Heunisch U, Krapp S, Charrow J, Schwake M, Kelleher NL, Silverman RB, Krainc D. ß-Glucocerebrosidase Modulators Promote Dimerization of ß-Glucocerebrosidase and Reveal an Allosteric Binding Site. J Am Chem Soc. 2018 05 09; 140(18):5914-5924. PMID: 29676907.
    Citations:    Fields:    Translation:HumansCells
  5. Collier TJ, Srivastava KR, Justman C, Grammatopoulous T, Hutter-Paier B, Prokesch M, Havas D, Rochet JC, Liu F, Jock K, de Oliveira P, Stirtz GL, Dettmer U, Sortwell CE, Feany MB, Lansbury P, Lapidus L, Paumier KL. Nortriptyline inhibits aggregation and neurotoxicity of alpha-synuclein by enhancing reconfiguration of the monomeric form. Neurobiol Dis. 2017 Oct; 106:191-204. PMID: 28711409.
    Citations: 2     Fields:    Translation:HumansAnimalsCells
  6. Vamvaca K, Lansbury PT, Stefanis L. N-terminal deletion does not affect a-synuclein membrane binding, self-association and toxicity in human neuroblastoma cells, unlike yeast. J Neurochem. 2011 Oct; 119(2):389-97. PMID: 21848810.
    Citations: 5     Fields:    Translation:HumansAnimalsCells
  7. Nowak RJ, Cuny GD, Choi S, Lansbury PT, Ray SS. Improving binding specificity of pharmacological chaperones that target mutant superoxide dismutase-1 linked to familial amyotrophic lateral sclerosis using computational methods. J Med Chem. 2010 Apr 08; 53(7):2709-18. PMID: 20232802.
    Citations: 10     Fields:    Translation:HumansCells
  8. Vamvaca K, Volles MJ, Lansbury PT. The first N-terminal amino acids of alpha-synuclein are essential for alpha-helical structure formation in vitro and membrane binding in yeast. J Mol Biol. 2009 Jun 05; 389(2):413-24. PMID: 19285989.
    Citations: 30     Fields:    Translation:AnimalsCells
  9. Liu Z, Meray RK, Grammatopoulos TN, Fredenburg RA, Cookson MR, Liu Y, Logan T, Lansbury PT. Membrane-associated farnesylated UCH-L1 promotes alpha-synuclein neurotoxicity and is a therapeutic target for Parkinson's disease. Proc Natl Acad Sci U S A. 2009 Mar 24; 106(12):4635-40. PMID: 19261853.
    Citations: 45     Fields:    Translation:HumansAnimalsCells
  10. Paleologou KE, Schmid AW, Rospigliosi CC, Kim HY, Lamberto GR, Fredenburg RA, Lansbury PT, Fernandez CO, Eliezer D, Zweckstetter M, Lashuel HA. Phosphorylation at Ser-129 but not the phosphomimics S129E/D inhibits the fibrillation of alpha-synuclein. J Biol Chem. 2008 Jun 13; 283(24):16895-905. PMID: 18343814.
    Citations: 96     Fields:    Translation:HumansCells
  11. Martinez-Vicente M, Talloczy Z, Kaushik S, Massey AC, Mazzulli J, Mosharov EV, Hodara R, Fredenburg R, Wu DC, Follenzi A, Dauer W, Przedborski S, Ischiropoulos H, Lansbury PT, Sulzer D, Cuervo AM. Dopamine-modified alpha-synuclein blocks chaperone-mediated autophagy. J Clin Invest. 2008 Feb; 118(2):777-88. PMID: 18172548.
    Citations: 203     Fields:    Translation:AnimalsCells
  12. Fredenburg RA, Rospigliosi C, Meray RK, Kessler JC, Lashuel HA, Eliezer D, Lansbury PT. The impact of the E46K mutation on the properties of alpha-synuclein in its monomeric and oligomeric states. Biochemistry. 2007 Jun 19; 46(24):7107-18. PMID: 17530780.
    Citations: 75     Fields:    Translation:HumansCells
  13. Meray RK, Lansbury PT. Reversible monoubiquitination regulates the Parkinson disease-associated ubiquitin hydrolase UCH-L1. J Biol Chem. 2007 Apr 06; 282(14):10567-75. PMID: 17259170.
    Citations: 29     Fields:    Translation:HumansAnimalsCells
  14. Follmer C, Romão L, Einsiedler CM, Porto TC, Lara FA, Moncores M, Weissmüller G, Lashuel HA, Lansbury P, Neto VM, Silva JL, Foguel D. Dopamine affects the stability, hydration, and packing of protofibrils and fibrils of the wild type and variants of alpha-synuclein. Biochemistry. 2007 Jan 16; 46(2):472-82. PMID: 17209557.
    Citations: 9     Fields:    Translation:HumansCells
  15. Volles MJ, Lansbury PT. Relationships between the sequence of alpha-synuclein and its membrane affinity, fibrillization propensity, and yeast toxicity. J Mol Biol. 2007 Mar 09; 366(5):1510-22. PMID: 17222866.
    Citations: 54     Fields:    Translation:HumansAnimalsCells
  16. Luchansky SJ, Lansbury PT, Stein RL. Substrate recognition and catalysis by UCH-L1. Biochemistry. 2006 Dec 12; 45(49):14717-25. PMID: 17144664.
    Citations: 11     Fields:    Translation:HumansCells
  17. Lansbury PT, Lashuel HA. A century-old debate on protein aggregation and neurodegeneration enters the clinic. Nature. 2006 Oct 19; 443(7113):774-9. PMID: 17051203.
    Citations: 166     Fields:    Translation:HumansAnimalsCells
  18. Lashuel HA, Lansbury PT. Are amyloid diseases caused by protein aggregates that mimic bacterial pore-forming toxins? Q Rev Biophys. 2006 May; 39(2):167-201. PMID: 16978447.
    Citations: 114     Fields:    Translation:HumansCells
  19. Lansbury PT. Improving synaptic function in a mouse model of AD. Cell. 2006 Aug 25; 126(4):655-7. PMID: 16923386.
    Citations: 3     Fields:    Translation:HumansAnimalsCells
  20. Das C, Hoang QQ, Kreinbring CA, Luchansky SJ, Meray RK, Ray SS, Lansbury PT, Ringe D, Petsko GA. Structural basis for conformational plasticity of the Parkinson's disease-associated ubiquitin hydrolase UCH-L1. Proc Natl Acad Sci U S A. 2006 Mar 21; 103(12):4675-80. PMID: 16537382.
    Citations: 51     Fields:    Translation:HumansCells
  21. Volles MJ, Lansbury PT. A computer program for the estimation of protein and nucleic acid sequence diversity in random point mutagenesis libraries. Nucleic Acids Res. 2005; 33(11):3667-77. PMID: 15990391.
    Citations: 6     Fields:    
  22. Ray SS, Nowak RJ, Brown RH, Lansbury PT. Small-molecule-mediated stabilization of familial amyotrophic lateral sclerosis-linked superoxide dismutase mutants against unfolding and aggregation. Proc Natl Acad Sci U S A. 2005 Mar 08; 102(10):3639-44. PMID: 15738401.
    Citations: 36     Fields:    Translation:HumansCells
  23. Lansbury PT, Fagan T. Your health in the 21st century. A fix for faulty proteins. Newsweek. 2005; 145(26A):52. PMID: 16375147.
    Citations:    Fields:    Translation:HumansCells
  24. Cuervo AM, Stefanis L, Fredenburg R, Lansbury PT, Sulzer D. Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. Science. 2004 Aug 27; 305(5688):1292-5. PMID: 15333840.
    Citations: 511     Fields:    Translation:AnimalsCells
  25. Lansbury PT. Back to the future: the 'old-fashioned' way to new medications for neurodegeneration. Nat Med. 2004 Jul; 10 Suppl:S51-7. PMID: 15298008.
    Citations: 23     Fields:    Translation:HumansAnimals
  26. Ray SS, Nowak RJ, Strokovich K, Brown RH, Walz T, Lansbury PT. An intersubunit disulfide bond prevents in vitro aggregation of a superoxide dismutase-1 mutant linked to familial amytrophic lateral sclerosis. Biochemistry. 2004 May 04; 43(17):4899-905. PMID: 15109247.
    Citations: 38     Fields:    Translation:HumansCells
  27. Ray SS, Lansbury PT. A possible therapeutic target for Lou Gehrig's disease. Proc Natl Acad Sci U S A. 2004 Apr 20; 101(16):5701-2. PMID: 15079068.
    Citations: 9     Fields:    Translation:HumansCells
  28. Rochet JC, Outeiro TF, Conway KA, Ding TT, Volles MJ, Lashuel HA, Bieganski RM, Lindquist SL, Lansbury PT. Interactions among alpha-synuclein, dopamine, and biomembranes: some clues for understanding neurodegeneration in Parkinson's disease. J Mol Neurosci. 2004; 23(1-2):23-34. PMID: 15126689.
    Citations: 58     Fields:    Translation:HumansAnimalsCells
  29. Kheterpal I, Lashuel HA, Hartley DM, Walz T, Lansbury PT, Wetzel R. Abeta protofibrils possess a stable core structure resistant to hydrogen exchange. Biochemistry. 2003 Dec 09; 42(48):14092-8. PMID: 14640676.
    Citations: 26     Fields:    Translation:HumansCells
  30. Lashuel HA, Hartley DM, Petre BM, Wall JS, Simon MN, Walz T, Lansbury PT. Mixtures of wild-type and a pathogenic (E22G) form of Abeta40 in vitro accumulate protofibrils, including amyloid pores. J Mol Biol. 2003 Sep 26; 332(4):795-808. PMID: 12972252.
    Citations: 64     Fields:    Translation:HumansAnimalsCells
  31. Liu Y, Lashuel HA, Choi S, Xing X, Case A, Ni J, Yeh LA, Cuny GD, Stein RL, Lansbury PT. Discovery of inhibitors that elucidate the role of UCH-L1 activity in the H1299 lung cancer cell line. Chem Biol. 2003 Sep; 10(9):837-46. PMID: 14522054.
    Citations: 60     Fields:    Translation:HumansCells
  32. Foguel D, Suarez MC, Ferrão-Gonzales AD, Porto TC, Palmieri L, Einsiedler CM, Andrade LR, Lashuel HA, Lansbury PT, Kelly JW, Silva JL. Dissociation of amyloid fibrils of alpha-synuclein and transthyretin by pressure reveals their reversible nature and the formation of water-excluded cavities. Proc Natl Acad Sci U S A. 2003 Aug 19; 100(17):9831-6. PMID: 12900507.
    Citations: 32     Fields:    Translation:Humans
  33. Volles MJ, Lansbury PT. Zeroing in on the pathogenic form of alpha-synuclein and its mechanism of neurotoxicity in Parkinson's disease. Biochemistry. 2003 Jul 08; 42(26):7871-8. PMID: 12834338.
    Citations: 104     Fields:    Translation:HumansAnimalsCells
  34. Caughey B, Lansbury PT. Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders. Annu Rev Neurosci. 2003; 26:267-98. PMID: 12704221.
    Citations: 446     Fields:    Translation:HumansAnimalsCells
  35. Park JY, Lansbury PT. Beta-synuclein inhibits formation of alpha-synuclein protofibrils: a possible therapeutic strategy against Parkinson's disease. Biochemistry. 2003 Apr 08; 42(13):3696-700. PMID: 12667059.
    Citations: 49     Fields:    Translation:HumansCells
  36. Kessler JC, Rochet JC, Lansbury PT. The N-terminal repeat domain of alpha-synuclein inhibits beta-sheet and amyloid fibril formation. Biochemistry. 2003 Jan 28; 42(3):672-8. PMID: 12534279.
    Citations: 34     Fields:    Translation:HumansCells
  37. Liu Y, Fallon L, Lashuel HA, Liu Z, Lansbury PT. The UCH-L1 gene encodes two opposing enzymatic activities that affect alpha-synuclein degradation and Parkinson's disease susceptibility. Cell. 2002 Oct 18; 111(2):209-18. PMID: 12408865.
    Citations: 177     Fields:    Translation:HumansAnimalsCells
  38. Lashuel HA, Petre BM, Wall J, Simon M, Nowak RJ, Walz T, Lansbury PT. Alpha-synuclein, especially the Parkinson's disease-associated mutants, forms pore-like annular and tubular protofibrils. J Mol Biol. 2002 Oct 04; 322(5):1089-102. PMID: 12367530.
    Citations: 190     Fields:    Translation:HumansAnimalsCells
  39. Lansbury PT, Brice A. Genetics of Parkinson's disease and biochemical studies of implicated gene products. Curr Opin Cell Biol. 2002 Oct; 14(5):653-60. PMID: 12231362.
    Citations: 16     Fields:    Translation:Humans
  40. Anguiano M, Nowak RJ, Lansbury PT. Protofibrillar islet amyloid polypeptide permeabilizes synthetic vesicles by a pore-like mechanism that may be relevant to type II diabetes. Biochemistry. 2002 Sep 24; 41(38):11338-43. PMID: 12234175.
    Citations: 89     Fields:    Translation:HumansCells
  41. Ding TT, Lee SJ, Rochet JC, Lansbury PT. Annular alpha-synuclein protofibrils are produced when spherical protofibrils are incubated in solution or bound to brain-derived membranes. Biochemistry. 2002 Aug 13; 41(32):10209-17. PMID: 12162735.
    Citations: 100     Fields:    Translation:HumansAnimalsCells
  42. Lashuel HA, Hartley D, Petre BM, Walz T, Lansbury PT. Neurodegenerative disease: amyloid pores from pathogenic mutations. Nature. 2002 Jul 18; 418(6895):291. PMID: 12124613.
    Citations: 323     Fields:    Translation:HumansCells
  43. Lansbury PT, Brice A. Genetics of Parkinson's disease and biochemical studies of implicated gene products. Curr Opin Genet Dev. 2002 Jun; 12(3):299-306. PMID: 12076673.
    Citations: 12     Fields:    Translation:HumansCells
  44. Volles MJ, Lansbury PT. Vesicle permeabilization by protofibrillar alpha-synuclein is sensitive to Parkinson's disease-linked mutations and occurs by a pore-like mechanism. Biochemistry. 2002 Apr 09; 41(14):4595-602. PMID: 11926821.
    Citations: 124     Fields:    Translation:HumansAnimalsCells
  45. Shtilerman MD, Ding TT, Lansbury PT. Molecular crowding accelerates fibrillization of alpha-synuclein: could an increase in the cytoplasmic protein concentration induce Parkinson's disease? Biochemistry. 2002 Mar 26; 41(12):3855-60. PMID: 11900526.
    Citations: 68     Fields:    Translation:HumansCells
  46. Conway KA, Rochet JC, Bieganski RM, Lansbury PT. Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct. Science. 2001 Nov 09; 294(5545):1346-9. PMID: 11701929.
    Citations: 268     Fields:    Translation:HumansAnimalsCells
  47. Volles MJ, Lee SJ, Rochet JC, Shtilerman MD, Ding TT, Kessler JC, Lansbury PT. Vesicle permeabilization by protofibrillar alpha-synuclein: implications for the pathogenesis and treatment of Parkinson's disease. Biochemistry. 2001 Jul 03; 40(26):7812-9. PMID: 11425308.
    Citations: 174     Fields:    Translation:HumansCells
  48. Lansbury PT. Following nature's anti-amyloid strategy. Nat Biotechnol. 2001 Feb; 19(2):112-3. PMID: 11175720.
    Citations: 4     Fields:    Translation:HumansCells
  49. Rochet JC, Conway KA, Lansbury PT. Inhibition of fibrillization and accumulation of prefibrillar oligomers in mixtures of human and mouse alpha-synuclein. Biochemistry. 2000 Sep 05; 39(35):10619-26. PMID: 10978144.
    Citations: 53     Fields:    Translation:HumansAnimalsCells
  50. Fezoui Y, Hartley DM, Harper JD, Khurana R, Walsh DM, Condron MM, Selkoe DJ, Lansbury PT, Fink AL, Teplow DB. An improved method of preparing the amyloid beta-protein for fibrillogenesis and neurotoxicity experiments. Amyloid. 2000 Sep; 7(3):166-78. PMID: 11019857.
    Citations: 54     Fields:    Translation:HumansAnimalsCells
  51. Goldberg MS, Lansbury PT. Is there a cause-and-effect relationship between alpha-synuclein fibrillization and Parkinson's disease? Nat Cell Biol. 2000 Jul; 2(7):E115-9. PMID: 10878819.
    Citations: 120     Fields:    Translation:HumansAnimals
  52. Conway KA, Harper JD, Lansbury PT. Fibrils formed in vitro from alpha-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid. Biochemistry. 2000 Mar 14; 39(10):2552-63. PMID: 10704204.
    Citations: 191     Fields:    Translation:HumansCells
  53. Rochet JC, Lansbury PT. Amyloid fibrillogenesis: themes and variations. Curr Opin Struct Biol. 2000 Feb; 10(1):60-8. PMID: 10679462.
    Citations: 208     Fields:    Translation:HumansAnimalsCells
  54. Conway KA, Lee SJ, Rochet JC, Ding TT, Williamson RE, Lansbury PT. Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. Proc Natl Acad Sci U S A. 2000 Jan 18; 97(2):571-6. PMID: 10639120.
    Citations: 372     Fields:    Translation:HumansCells
  55. Conway KA, Lee SJ, Rochet JC, Ding TT, Harper JD, Williamson RE, Lansbury PT. Accelerated oligomerization by Parkinson's disease linked alpha-synuclein mutants. Ann N Y Acad Sci. 2000; 920:42-5. PMID: 11193175.
    Citations: 65     Fields:    Translation:Humans
  56. Lansbury PT, Kosik KS. Neurodegeneration: new clues on inclusions. Chem Biol. 2000 Jan; 7(1):R9-R12. PMID: 10662685.
    Citations: 3     Fields:    Translation:HumansCells
  57. Lansbury PT. Yeast prions: bungee cord domains' balancing act. Curr Biol. 1999 Nov 18; 9(22):R845-7. PMID: 10574755.
    Citations:    Fields:    Translation:HumansAnimalsCells
  58. Caughey B, Raymond GJ, Priola SA, Kocisko DA, Race RE, Bessen RA, Lansbury PT, Chesebro B. Methods for studying prion protein (PrP) metabolism and the formation of protease-resistant PrP in cell culture and cell-free systems. An update. Mol Biotechnol. 1999 Nov; 13(1):45-55. PMID: 10934521.
    Citations: 9     Fields:    Translation:HumansAnimalsCells
  59. Koo EH, Lansbury PT, Kelly JW. Amyloid diseases: abnormal protein aggregation in neurodegeneration. Proc Natl Acad Sci U S A. 1999 Aug 31; 96(18):9989-90. PMID: 10468546.
    Citations: 115     Fields:    Translation:Humans
  60. Zhen W, Han H, Anguiano M, Lemere CA, Cho CG, Lansbury PT. Synthesis and amyloid binding properties of rhenium complexes: preliminary progress toward a reagent for SPECT imaging of Alzheimer's disease brain. J Med Chem. 1999 Jul 29; 42(15):2805-15. PMID: 10425090.
    Citations: 8     Fields:    Translation:Humans
  61. Harper JD, Wong SS, Lieber CM, Lansbury PT. Assembly of A beta amyloid protofibrils: an in vitro model for a possible early event in Alzheimer's disease. Biochemistry. 1999 Jul 13; 38(28):8972-80. PMID: 10413470.
    Citations: 96     Fields:    Translation:HumansCells
  62. Lansbury PT. Evolution of amyloid: what normal protein folding may tell us about fibrillogenesis and disease. Proc Natl Acad Sci U S A. 1999 Mar 30; 96(7):3342-4. PMID: 10097040.
    Citations: 103     Fields:    Translation:HumansAnimalsCells
  63. Conway KA, Harper JD, Lansbury PT. Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease. Nat Med. 1998 Nov; 4(11):1318-20. PMID: 9809558.
    Citations: 340     Fields:    Translation:HumansCells
  64. Lee SJ, Liyanage U, Bickel PE, Xia W, Lansbury PT, Kosik KS. A detergent-insoluble membrane compartment contains A beta in vivo. Nat Med. 1998 Jun; 4(6):730-4. PMID: 9623986.
    Citations: 93     Fields:    Translation:AnimalsCells
  65. Lansbury PT. Structural neurology: are seeds at the root of neuronal degeneration? Neuron. 1997 Dec; 19(6):1151-4. PMID: 9427238.
    Citations: 34     Fields:    Translation:HumansCells
  66. Harper JD, Lieber CM, Lansbury PT. Atomic force microscopic imaging of seeded fibril formation and fibril branching by the Alzheimer's disease amyloid-beta protein. Chem Biol. 1997 Dec; 4(12):951-9. PMID: 9427660.
    Citations: 100     Fields:    Translation:HumansCells
  67. Lansbury PT. Yeast prions: inheritance by seeded protein polymerization? Curr Biol. 1997 Oct 01; 7(10):R617-9. PMID: 9368740.
    Citations:    Fields:    Translation:Animals
  68. Lansbury PT. Inhibition of amyloid formation: a strategy to delay the onset of Alzheimer's disease. Curr Opin Chem Biol. 1997 Aug; 1(2):260-7. PMID: 9667848.
    Citations: 8     Fields:    Translation:Humans
  69. Raymond GJ, Hope J, Kocisko DA, Priola SA, Raymond LD, Bossers A, Ironside J, Will RG, Chen SG, Petersen RB, Gambetti P, Rubenstein R, Smits MA, Lansbury PT, Caughey B. Molecular assessment of the potential transmissibilities of BSE and scrapie to humans. Nature. 1997 Jul 17; 388(6639):285-8. PMID: 9230438.
    Citations: 49     Fields:    Translation:HumansAnimalsCells
  70. Caughey B, Raymond GJ, Kocisko DA, Lansbury PT. Scrapie infectivity correlates with converting activity, protease resistance, and aggregation of scrapie-associated prion protein in guanidine denaturation studies. J Virol. 1997 May; 71(5):4107-10. PMID: 9094691.
    Citations: 20     Fields:    Translation:AnimalsCells
  71. Harper JD, Wong SS, Lieber CM, Lansbury PT. Observation of metastable Abeta amyloid protofibrils by atomic force microscopy. Chem Biol. 1997 Feb; 4(2):119-25. PMID: 9190286.
    Citations: 154     Fields:    Translation:Humans
  72. Harper JD, Lansbury PT. Models of amyloid seeding in Alzheimer's disease and scrapie: mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins. Annu Rev Biochem. 1997; 66:385-407. PMID: 9242912.
    Citations: 336     Fields:    Translation:HumansAnimalsCells
  73. Weinreb PH, Zhen W, Poon AW, Conway KA, Lansbury PT. NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded. Biochemistry. 1996 Oct 29; 35(43):13709-15. PMID: 8901511.
    Citations: 354     Fields:    Translation:HumansCells
  74. Kocisko DA, Lansbury PT, Caughey B. Partial unfolding and refolding of scrapie-associated prion protein: evidence for a critical 16-kDa C-terminal domain. Biochemistry. 1996 Oct 15; 35(41):13434-42. PMID: 8873612.
    Citations: 31     Fields:    Translation:AnimalsCells
  75. Lansbury PT, Caughey B. The double life of the prion protein. Curr Biol. 1996 Aug 01; 6(8):914-6. PMID: 8805340.
    Citations: 1     Fields:    Translation:Animals
  76. Ashburn TT, Han H, McGuinness BF, Lansbury PT. Amyloid probes based on Congo Red distinguish between fibrils comprising different peptides. Chem Biol. 1996 May; 3(5):351-8. PMID: 8807864.
    Citations: 8     Fields:    Translation:Cells
  77. Caughey B, Kocisko DA, Raymond GJ, Lansbury PT. Aggregates of scrapie-associated prion protein induce the cell-free conversion of protease-sensitive prion protein to the protease-resistant state. Chem Biol. 1995 Dec; 2(12):807-17. PMID: 8807814.
    Citations: 39     Fields:    Translation:AnimalsCells
  78. Lansbury PT, Costa PR, Griffiths JM, Simon EJ, Auger M, Halverson KJ, Kocisko DA, Hendsch ZS, Ashburn TT, Spencer RG, et al. Structural model for the beta-amyloid fibril based on interstrand alignment of an antiparallel-sheet comprising a C-terminal peptide. Nat Struct Biol. 1995 Nov; 2(11):990-8. PMID: 7583673.
    Citations: 78     Fields:    Translation:HumansCells
  79. Bessen RA, Kocisko DA, Raymond GJ, Nandan S, Lansbury PT, Caughey B. Non-genetic propagation of strain-specific properties of scrapie prion protein. Nature. 1995 Jun 22; 375(6533):698-700. PMID: 7791905.
    Citations: 116     Fields:    Translation:Animals
  80. Kocisko DA, Priola SA, Raymond GJ, Chesebro B, Lansbury PT, Caughey B. Species specificity in the cell-free conversion of prion protein to protease-resistant forms: a model for the scrapie species barrier. Proc Natl Acad Sci U S A. 1995 Apr 25; 92(9):3923-7. PMID: 7732006.
    Citations: 78     Fields:    Translation:AnimalsCells
  81. Han H, Weinreb PH, Lansbury PT. The core Alzheimer's peptide NAC forms amyloid fibrils which seed and are seeded by beta-amyloid: is NAC a common trigger or target in neurodegenerative disease? Chem Biol. 1995 Mar; 2(3):163-9. PMID: 9383418.
    Citations: 55     Fields:    Translation:HumansCells
  82. Lansbury PT. Consequences of the molecular mechanism of amyloid formation for the understanding of the pathogenesis of Alzheimer's disease and the development of therapeutic strategies. Arzneimittelforschung. 1995 Mar; 45(3A):432-4. PMID: 7763339.
    Citations: 1     Fields:    Translation:Humans
  83. Evans KC, Berger EP, Cho CG, Weisgraber KH, Lansbury PT. Apolipoprotein E is a kinetic but not a thermodynamic inhibitor of amyloid formation: implications for the pathogenesis and treatment of Alzheimer disease. Proc Natl Acad Sci U S A. 1995 Jan 31; 92(3):763-7. PMID: 7846048.
    Citations: 58     Fields:    Translation:HumansCells
  84. Lansbury PT, Caughey B. The chemistry of scrapie infection: implications of the 'ice 9' metaphor. Chem Biol. 1995 Jan; 2(1):1-5. PMID: 9383397.
    Citations: 37     Fields:    Translation:HumansAnimals
  85. Lansbury PT. Mechanism of scrapie replication. Science. 1994 Sep 09; 265(5178):1510. PMID: 8079159.
    Citations: 4     Fields:    Translation:Cells
  86. Kocisko DA, Come JH, Priola SA, Chesebro B, Raymond GJ, Lansbury PT, Caughey B. Cell-free formation of protease-resistant prion protein. Nature. 1994 Aug 11; 370(6489):471-4. PMID: 7913989.
    Citations: 183     Fields:    Translation:HumansAnimalsCells
  87. Jarrett JT, Berger EP, Lansbury PT. The C-terminus of the beta protein is critical in amyloidogenesis. Ann N Y Acad Sci. 1993 Sep 24; 695:144-8. PMID: 8239273.
    Citations: 55     Fields:    Translation:Humans
  88. Come JH, Fraser PE, Lansbury PT. A kinetic model for amyloid formation in the prion diseases: importance of seeding. Proc Natl Acad Sci U S A. 1993 Jul 01; 90(13):5959-63. PMID: 8327467.
    Citations: 88     Fields:    Translation:HumansCells
  89. Jarrett JT, Lansbury PT. Seeding "one-dimensional crystallization" of amyloid: a pathogenic mechanism in Alzheimer's disease and scrapie? Cell. 1993 Jun 18; 73(6):1055-8. PMID: 8513491.
    Citations: 424     Fields:    Translation:HumansAnimals
  90. Jarrett JT, Berger EP, Lansbury PT. The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. Biochemistry. 1993 May 11; 32(18):4693-7. PMID: 8490014.
    Citations: 366     Fields:    Translation:HumansCells
  91. Jarrett JT, Lansbury PT. Amyloid fibril formation requires a chemically discriminating nucleation event: studies of an amyloidogenic sequence from the bacterial protein OsmB. Biochemistry. 1992 Dec 15; 31(49):12345-52. PMID: 1463722.
    Citations: 61     Fields:    Translation:Cells
  92. Lansbury PT. In pursuit of the molecular structure of amyloid plaque: new technology provides unexpected and critical information. Biochemistry. 1992 Aug 04; 31(30):6865-70. PMID: 1637821.
    Citations: 24     Fields:    Translation:Cells
  93. Lellouch AC, Lansbury PT. A peptide model for the heparin binding site of antithrombin III. Biochemistry. 1992 Mar 03; 31(8):2279-85. PMID: 1540583.
    Citations: 5     Fields:    Translation:HumansAnimalsCells
  94. Spencer RG, Halverson KJ, Auger M, McDermott AE, Griffin RG, Lansbury PT. An unusual peptide conformation may precipitate amyloid formation in Alzheimer's disease: application of solid-state NMR to the determination of protein secondary structure. Biochemistry. 1991 Oct 29; 30(43):10382-7. PMID: 1931962.
    Citations: 11     Fields:    Translation:HumansCells
  95. Halverson K, Fraser PE, Kirschner DA, Lansbury PT. Molecular determinants of amyloid deposition in Alzheimer's disease: conformational studies of synthetic beta-protein fragments. Biochemistry. 1990 Mar 20; 29(11):2639-44. PMID: 2346740.
    Citations: 56     Fields:    Translation:HumansCells
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact feedbackcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Lansbury's Networks
Click the
buttons for more information and interactive visualizations!
Concepts (347)
Co-Authors (7)
Similar People (60)
Same Department 
Physical Neighbors
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.